MAP2K7 and thyroid gland carcinoma: The treatment of advanced thyroid carcinomas as PDTC and ATC with BRAF inhibitor dabrafenib and MEK inhibitor trametinib have shown significant redifferentiation and response rates in BRAF-mutated tumors [69–71].